痛風治療薬市場：薬剤クラス別、治療法、投与経路、用途-2025年～2030年の世界予測

痛風治療薬市場は、2023年に27億5,000万米ドルと評価され、2024年には30億5,000万米ドルに達すると予測され、CAGR 10.95%で成長し、2030年には57億米ドルに達すると予測されています。

痛風治療薬の範囲と定義は、関節の突然の痛み、腫れ、発赤を特徴とする炎症性関節炎の一種である痛風に関連する症状を管理・緩和するために開発された医薬品と治療法を包含します。痛風治療薬の必要性は、ライフスタイル要因や高齢化により、この疾患の有病率が増加していることに起因しています。これらの治療薬は、急性痛風発作、慢性管理、および併存疾患のリスクを最小限に抑えながらの再発予防に応用されます。最終用途には主に病院、診療所、専門のリウマチセンターが含まれ、そこでオーダーメイドの治療レジメンが実施されます。市場の成長は、痛風の罹患率の上昇、生物学的製剤の進歩、早期診断や治療オプションに関するヘルスケアプロバイダーや患者の意識の高まりといった要因に影響されています。尿酸降下療法や生物学的製剤を含む新規治療薬のイントロダクションは、潜在的な市場機会をもたらします。こうした機会を捉えるための提言としては、革新的な治療法の研究開発への投資や、世界な販売網を強化するための戦略的パートナーシップの締結などが挙げられます。しかし、市場の成長は、高い治療費、潜在的な副作用、迅速な市場承認と幅広い普及を妨げる厳しい規制要件などの限界に直面しています。さらに、長期にわたる治療レジメンに対する患者のアドヒアランスの課題や、新興市場における認知度の低さが、市場のダイナミクスをさらに複雑にしています。こうした課題にもかかわらず、個別化医療、バイオシミラーの開発、治療最適化における予測分析へのAIの活用といった革新的な領域が、研究と事業成長の道を開いています。市場の競争は依然として激しく、主要企業は買収や提携を通じてポートフォリオの拡大に注力しており、大きな市場シェアを獲得するためには絶え間ない革新と適応が必要です。成長を目指す企業は、包括的な患者中心のアプローチ、デジタルヘルス技術の活用、痛風と併存する疾患の総合的な管理への対応に注力すべきです。

市場力学：急速に進化する痛風治療薬市場の主要市場インサイトを公開

痛風治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • アルコール消費量の増加に伴う痛風の有病率の上昇
  • 老年人口の増加
  • 尿酸降下剤セグメントのイントロダクション
• 市場抑制要因
  • ジェネリック医薬品との競合と薬価の高騰
• 市場機会
  • 画像診断技術の進歩による痛風に対する理解の向上
  • 再生医療に関する研究開発の活発化
• 市場の課題
  • 痛風治療薬の副作用

ポーターの5つの力：痛風治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：痛風治療薬市場における外部からの影響の把握

外部マクロ環境要因は、痛風治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析痛風治療薬市場における競合情勢の把握

痛風治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス痛風治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、痛風治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨痛風治療薬市場における成功への道筋を描く

痛風治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • アルコール消費量の増加に伴う痛風の罹患率の上昇
    • 高齢化人口の増加
    • 尿酸降下剤セグメントのイントロダクション
  • 抑制要因
    • ジェネリック医薬品との競合と医薬品の高コスト
  • 機会
    • 画像診断技術の進歩により痛風の理解が深まりました
    • 再生医療の研究開発活動の拡大
  • 課題
    • 痛風治療薬の副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 痛風治療薬市場：薬剤クラス別

• コルヒチン
• コルチコステロイド
• NSAIDs
• 尿酸値を下げる薬

第7章 痛風治療薬市場：治療法別

• 尿酸尿治療薬
• キサンチンオキシダーゼ阻害剤

第8章 痛風治療薬市場：投与経路別

• 経口
• 非経口

第9章 痛風治療薬市場：用途別

• 急性痛風
• 慢性痛風

第10章 南北アメリカの痛風治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の痛風治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの痛風治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Astellas Pharma Inc.
• AstraZeneca PLC
• Bristol Myers Squibb Company
• C.H. Boehringer Sohn AG & Co. KG
• GlaxoSmithKline PLC
• Hikma Pharmaceuticals PLC
• Horizon Pharma PLC
• Lannett Company, Inc.
• Merck & Co., Inc.
• Novartis AG
• Regeneron Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Teijin Limited
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

LIST OF FIGURES

• FIGURE 1. GOUT THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. GOUT THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GOUT THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. GOUT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. GOUT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GOUT THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GOUT THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GOUT THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY COLCHICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URATE-LOWERING AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY URICOSURIA MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY XANTHINE OXIDASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY ACUTE GOUT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL GOUT THERAPEUTICS MARKET SIZE, BY CHRONIC GOUT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. CANADA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. CANADA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 36. CANADA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 37. CANADA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES GOUT THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. CHINA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. CHINA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 58. CHINA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 59. CHINA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. INDIA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 61. INDIA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 62. INDIA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. INDIA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. SINGAPORE GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH KOREA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. TAIWAN GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. THAILAND GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. VIETNAM GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA GOUT THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 105. DENMARK GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. EGYPT GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. FINLAND GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. ISRAEL GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. ITALY GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 130. ITALY GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 131. ITALY GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. ITALY GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. NETHERLANDS GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. NIGERIA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. NORWAY GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. POLAND GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 146. POLAND GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 147. POLAND GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 148. POLAND GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. QATAR GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 150. QATAR GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 151. QATAR GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 152. QATAR GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. SAUDI ARABIA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH AFRICA GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. SWEDEN GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. SWITZERLAND GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. TURKEY GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. UNITED ARAB EMIRATES GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM GOUT THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. GOUT THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 190. GOUT THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Gout Therapeutics Market was valued at USD 2.75 billion in 2023, expected to reach USD 3.05 billion in 2024, and is projected to grow at a CAGR of 10.95%, to USD 5.70 billion by 2030.

The scope and definition of gout therapeutics encompass medications and treatments developed to manage and alleviate symptoms associated with gout, a form of inflammatory arthritis characterized by sudden pain, swelling, and redness in the joints. The necessity of gout therapeutics arises from the increasing prevalence of the condition, driven by lifestyle factors and ageing populations. These therapeutics find application in acute gout attacks, chronic management, and prevention of recurrence while minimizing the risk of comorbidities. End-use scope mainly involves hospitals, clinics, and specialized rheumatology centers where tailored treatment regimens are administered. Market growth is influenced by factors such as the rising incidence of gout, advancements in biologics, and increasing awareness amongst healthcare providers and patients regarding early diagnosis and treatment options. The introduction of novel therapies, including urate-lowering therapies and biologics, presents potential market opportunities. Recommendations to seize these opportunities include investing in R&D for innovative therapies and engaging in strategic partnerships to enhance distribution networks globally. However, market growth faces limitations such as high treatment costs, potential side effects, and stringent regulatory requirements that hinder quick market approvals and wider adoption. Additionally, challenges in patient adherence to long-term treatment regimens and limited awareness in emerging markets further complicate market dynamics. Despite these challenges, areas of innovation such as personalized medicine, development of biosimilars, and the use of AI for predictive analytics in treatment optimization open avenues for research and business growth. The nature of the market remains competitive, with key players focusing on expanding their portfolios through acquisitions and collaborations, necessitating constant innovation and adaptation to capture significant market share. Companies striving for growth should focus on comprehensive patient-centric approaches, leveraging digital health technologies and addressing the holistic management of comorbid conditions along with gout.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gout Therapeutics Market

The Gout Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of Gout with increasing alcohol consumption
  • Growing geriatric population
  • Introduction to urate-lowering agents segment
• Market Restraints
  • Competition from generic drugs and high cost of drugs
• Market Opportunities
  • Technological advancements in imaging modalities improved understanding of gout
  • Increasing R&D activities on regenerative medicines
• Market Challenges
  • Side Effects of Gout Therapeutic Drugs

Porter's Five Forces: A Strategic Tool for Navigating the Gout Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gout Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gout Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gout Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gout Therapeutics Market

A detailed market share analysis in the Gout Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gout Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gout Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gout Therapeutics Market

A strategic analysis of the Gout Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gout Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bristol Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Horizon Pharma PLC, Lannett Company, Inc., Merck & Co., Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Teijin Limited, Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Gout Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Colchicine, Corticosteroids, NSAIDs, and Urate-Lowering Agents.
• Based on Treatment, market is studied across Uricosuria Medication and Xanthine Oxidase Inhibitor.
• Based on Route of Administration, market is studied across Oral and Parenteral.
• Based on Application, market is studied across Acute Gout and Chronic Gout.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of Gout with increasing alcohol consumption
    • 5.1.1.2. Growing geriatric population
    • 5.1.1.3. Introduction to urate-lowering agents segment
  • 5.1.2. Restraints
    • 5.1.2.1. Competition from generic drugs and high cost of drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in imaging modalities improved understanding of gout
    • 5.1.3.2. Increasing R&D activities on regenerative medicines
  • 5.1.4. Challenges
    • 5.1.4.1. Side Effects of Gout Therapeutic Drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Gout Therapeutics Market, by Drug Class

• 6.1. Introduction
• 6.2. Colchicine
• 6.3. Corticosteroids
• 6.4. NSAIDs
• 6.5. Urate-Lowering Agents

7. Gout Therapeutics Market, by Treatment

• 7.1. Introduction
• 7.2. Uricosuria Medication
• 7.3. Xanthine Oxidase Inhibitor

8. Gout Therapeutics Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral

9. Gout Therapeutics Market, by Application

• 9.1. Introduction
• 9.2. Acute Gout
• 9.3. Chronic Gout

10. Americas Gout Therapeutics Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Gout Therapeutics Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Gout Therapeutics Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Astellas Pharma Inc.
• 2. AstraZeneca PLC
• 3. Bristol Myers Squibb Company
• 4. C.H. Boehringer Sohn AG & Co. KG
• 5. GlaxoSmithKline PLC
• 6. Hikma Pharmaceuticals PLC
• 7. Horizon Pharma PLC
• 8. Lannett Company, Inc.
• 9. Merck & Co., Inc.
• 10. Novartis AG
• 11. Regeneron Pharmaceuticals, Inc.
• 12. Takeda Pharmaceutical Company Limited
• 13. Teijin Limited
• 14. Teva Pharmaceutical Industries Ltd.
• 15. Viatris Inc.